The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations

Journal of Clinical and Experimental Hepatology

Volumn 4, Issue , 2014, Pages S3-S26

  Kumar, Ashish ^a   Acharya, Subrat K ^b   Singh, Shivaram P ^c   Saraswat, Vivek A ^d   Arora, Anil ^a   Duseja, Ajay ^e   Goenka, Mahesh K ^f   Jain, Deepali ^b   Kar, Premashish ^g   Kumar, Manoj ^h   Kumaran, Vinay ^a   Mohandas, Kunisshery M ⁱ   Panda, Dipanjan ^h   Paul, Shashi B ^b   Ramachandran, Jeyamani ^j   Ramesh, Hariharan ^k   Rao, Padaki N ^l   Shah, Samir R ^m   Sharma, Hanish ^h   Thandassery, Ragesh B ^l  

^a SIR GANGA RAM HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c SCB MEDICAL COLLEGE   (India)

^d SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^e POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^f Apollo Gleneagles Hospital   (India)

^g MAULANA AZAD MEDICAL COLLEGE   (India)

^h INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

ⁱ Tata Medical Center ^*  (India)

^j CHRISTIAN MEDICAL COLLEGE   (India)

^k Lakeshore Hospital and Research Center ^*  (India)

^l ASIAN INSTITUTE OF GASTROENTEROLOGY   (India)

^m JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

more..

Author keywords

Liver cancer; RFA; TACE; Targeted therapy; Transplant

Indexed keywords

ABLATION THERAPY; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CHEMOEMBOLIZATION; DIABETES MELLITUS; ECHOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; INDIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER RESECTION; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR; TREATMENT RESPONSE;

EID: 84954196942     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2014.04.003     Document Type: Review

References (223)

1. CEBM > EBM Tools > Finding the Evidence > Levels of Evidence 2 > Levels of Evidence 1. Available at: . Accessed 24.02.13. http://www.cebm.net/index.aspx?o=1025.
2. PBCR Reports 2006-2008. . . Available at: . Accessed 24.02.13. http://www.ncrpindia.org/Reports/PBCR_2006_2008.aspx.
3. Cancer Incidence in Five Continents. Available at: . Accessed 24.02.13. http://ci5.iarc.fr/.
4. Dikshit R., Gupta P.C., Ramasundarahettige C., et al. Cancer mortality in India: a nationally representative survey. Lancet 2012, 379(9828):1807-1816.
5. El-Serag H.B. Hepatocellular carcinoma. N Engl J Med 2011, 365(12):1118-1127. 10.1056/NEJMra1001683.
6. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132(7):2557-2576. 10.1053/j.gastro.2007.04.061.
7. Paul S.B., Sreenivas V., Gulati M.S., et al. Incidence of hepatocellular carcinoma among Indian patients with cirrhosis of liver: an experience from a tertiary care center in northern India. Indian J Gastroenterol 2007, 26(6):274-278.
8. Yeole B.B. Trends in cancer incidence in esophagus, stomach, colon, rectum and liver in males in India. Asian Pac J Cancer Prev 2008, 9(1):97-100.
9. Herbst D.A., Reddy K.R. Risk factors for hepatocellular carcinoma. Clin Liver Dis 2012, 1(6):180-182.
10. Nayak N.C. Hepatocellular carcinoma-a model of human cancer: clinico-pathological features, etiology and pathogenesis. Indian J Pathol Microbiol 2003, 46(1):1-16.
11. Yang W.-S., Va P., Bray F., et al. The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies. PLoS ONE 2011, 6(12):e27326. 10.1371/journal.pone.0027326.
12. Wang P., Kang D., Cao W., Wang Y., Liu Z. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 2012, 28(2):109-122. 10.1002/dmrr.1291.
13. Wang C., Wang X., Gong G., et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer 2012, 130(7):1639-1648. 10.1002/ijc.26165.
14. Sundaram C., Reddy C.R., Ramana G.V., et al. Hepatitis B surface antigen, hepatocellular carcinoma and cirrhosis in south India-an autopsy study. Indian J Pathol Microbiol 1990, 33(4):334-338.
15. Ramesh R., Munshi A., Panda S.K. Prevalence of hepatitis C virus antibodies in chronic liver disease and hepatocellular carcinoma patients in India. J Gastroenterol Hepatol 1992, 7(4):393-395.
16. Sarin S.K., Thakur V., Guptan R.C., et al. Profile of hepatocellular carcinoma in India: an insight into the possible etiologic associations. J Gastroenterol Hepatol 2001, 16(6):666-673.
17. Saini N., Bhagat A., Sharma S., Duseja A., Chawla Y. Evaluation of clinical and biochemical parameters in hepatocellular carcinoma: experience from an Indian center. Clin Chim Acta 2006, 371(1-2):183-186. 10.1016/j.cca.2006.02.038.
18. Kumar M., Kumar R., Hissar S.S., et al. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from India. J Gastroenterol Hepatol 2007, 22(7):1104-1111. 10.1111/j.1440-1746.2007.04908.x.
19. Murugavel K.G., Naranatt P.P., Shankar E.M., et al. Prevalence of aflatoxin B1 in liver biopsies of proven hepatocellular carcinoma in India determined by an in-house immunoperoxidase test. J Med Microbiol 2007, 56(Pt 11):1455-1459. 10.1099/jmm.0.47151-0.
20. Kumar R., Saraswat M.K., Sharma B.C., Sakhuja P., Sarin S.K. Characteristics of hepatocellular carcinoma in India: a retrospective analysis of 191 cases. QJM 2008, 101(6):479-485. 10.1093/qjmed/hcn033.
21. Paul S.B., Chalamalasetty S.B., Vishnubhatla S., et al. Clinical profile, etiology and therapeutic outcome in 324 hepatocellular carcinoma patients at a tertiary care center in India. Oncology 2009, 77(3-4):162-171. 10.1159/000231886.
22. Asim M., Sarma M.P., Thayumanavan L., Kar P. Role of aflatoxin B1 as a risk for primary liver cancer in north Indian population. Clin Biochem 2011, 44(14-15):1235-1240. 10.1016/j.clinbiochem.2011.07.017.
23. Sarma M.P., Asim M., Medhi S., Bharathi T., Kar P. Hepatitis C virus related hepatocellular carcinoma: a case control study from India. J Med Virol 2012, 84(7):1009-1017. 10.1002/jmv.23290.
24. Jain D., Nayak N.C., Saigal S. Hepatocellular carcinoma in nonalcoholic fatty liver cirrhosis and alcoholic cirrhosis: risk factor analysis in liver transplant recipients. Eur J Gastroenterol Hepatol 2012, 24(7):840-848. 10.1097/MEG.0b013e3283534b40.
25. Nayak N.C., Jain D., Vasdev N., Gulwani H., Saigal S., Soin A. Etiologic types of end-stage chronic liver disease in adults: analysis of prevalence and their temporal changes from a study on native liver explants. Eur J Gastroenterol Hepatol 2012, 24(10):1199-1208. 10.1097/MEG.0b013e32835643f1.
26. Asim M., Sarma M.P., Kar P. Etiological and molecular profile of hepatocellular cancer from India. Int J Cancer 2013, 133(2):437-445. 10.1002/ijc.27993.
27. Duseja A., Sharma B., Kumar A., et al. Nonalcoholic fatty liver in a developing country is responsible for significant liver disease. Hepatology 2010, 52(6):2248-2249. 10.1002/hep.23838.
28. Amarapurkar D.N., Patel N.D., Kamani P.M. Impact of diabetes mellitus on outcome of HCC. Ann Hepatol 2008, 7(2):148-151.
29. Amarapurkar D., Das H.S. Chronic liver disease in diabetes mellitus. Trop Gastroenterol 2002, 23(1):3-5.
30. Asim M., Khan L.A., Husain S.A., et al. Genetic polymorphism of glutathione S transferases M1 and T1 in Indian patients with hepatocellular carcinoma. Dis Markers 2010, 28(6):369-376. 10.3233/DMA-2010-0717.
31. Bharadwaj M., Roy G., Dutta K., Misbah M., Husain M., Hussain S. Tackling hepatitis B virus-associated hepatocellular carcinoma - the future is now. Cancer Metastasis Rev. 2013, 32(1-2):229-268. 10.1007/s10555-012-9412-6.
32. Jayshree R.S., Sridhar H., Devi G.M. Surface, core, and X genes of hepatitis B virus in hepatocellular carcinoma: an in situ hybridization study. Cancer 2003, 99(1):63-67. 10.1002/cncr.10954.
33. Ramesh R., Panda S.K., Jameel S., Rajasambandam P. Mapping of the hepatitis B virus genome in hepatocellular carcinoma using PCR and demonstration of a potential trans-activator encoded by the frequently detected fragment. J Gen Virol 1994, 75(Pt 2):327-334.
34. Asim M., Malik A., Sarma M.P., et al. Hepatitis B virus BCP, precore/core, X gene mutations/genotypes and the risk of hepatocellular carcinoma in India. J Med Virol 2010, 82(7):1115-1125. 10.1002/jmv.21774.
35. Kiran M., Chawla Y.K., Kaur J. Methylation profiling of tumor suppressor genes and oncogenes in hepatitis virus-related hepatocellular carcinoma in northern India. Cancer Genet Cytogenet 2009, 195(2):112-119. 10.1016/j.cancergencyto.2009.06.021.
36. Saini N., Srinivasan R., Chawla Y., Sharma S., Chakraborti A., Rajwanshi A. Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status. Liver Int 2009, 29(8):1162-1170. 10.1111/j.1478-3231.2009.02082.x.
37. Sarin S.K., Kumar M. Predictive scores for hepatocellular carcinoma development in chronic hepatitis B virus infection: "does one size fit all?". Gastroenterology 2012, 142(4):1038-1040. 10.1053/j.gastro.2012.02.024.
38. Poduri C.D. Hepatitis C virus (HCV)-a review molecular biology of the virus, immunodiagnostics, genomic heterogeneity and the role of virus in hepatocellular carcinoma. Indian J Exp Biol 2003, 41(6):549-562.
39. Kiran M., Chawla Y.K., Kaur J. Glutathione-S-transferase and microsomal epoxide hydrolase polymorphism and viral-related hepatocellular carcinoma risk in India. DNA Cell Biol 2008, 27(12):687-694. 10.1089/dna.2008.0805.
40. Katiyar S., Dash B.C., Thakur V., Guptan R.C., Sarin S.K., Das B.C. P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India. Cancer 2000, 88(7):1565-1573.
41. Mohana Devi S., Balachandar V., Arun M., Suresh Kumar S., Balamurali Krishnan B., Sasikala K. Analysis of genetic damage and gene polymorphism in hepatocellular carcinoma (HCC) patients in a South Indian population. Dig Dis Sci. 2013, 58(3):759-767. 10.1007/s10620-012-2409-8.
42. Kiran M., Saxena R., Chawla Y.K., Kaur J. Polymorphism of DNA repair gene XRCC1 and hepatitis-related hepatocellular carcinoma risk in Indian population. Mol Cell Biochem 2009, 327(1-2):7-13. 10.1007/s11010-009-0035-3.
43. Kiran M., Chawla Y.K., Jain M., Kaur J. Haplotypes of microsomal epoxide hydrolase and X-ray cross-complementing group 1 genes in Indian hepatocellular carcinoma patients. DNA Cell Biol 2009, 28(11):573-577. 10.1089/dna.2009.0921.
44. Paul S.B., Sreenivas V., Gulati M.S., et al. Economic evaluation of a surveillance program of hepatocellular carcinoma (HCC) in India. Hepatol Int 2008, 2(2):231-236. 10.1007/s12072-008-9054-5.
45. Chang M.H., Chen C.J., Lai M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997, 336(26):1855-1859. 10.1056/NEJM199706263362602.
46. Liaw Y.-F., Sung J.J.Y., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351(15):1521-1531. 10.1056/NEJMoa033364.
47. Lai C.-L., Yuen M.-F. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 2013, 57(1):399-408. 10.1002/hep.25937.
48. Chakrabarty S.P., Murray J.M. Modelling hepatitis C virus infection and the development of hepatocellular carcinoma. J Theor Biol 2012, 305:24-29. 10.1016/j.jtbi.2012.03.030.
49. Singal A.G., Volk M.L., Jensen D., Di Bisceglie A.M., Schoenfeld P.S. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010, 8(3):280-288. 288.e1. 10.1016/j.cgh.2009.11.018.
50. Singal A.K., Singh A., Jaganmohan S., et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010, 8(2):192-199. 10.1016/j.cgh.2009.10.026.
51. Di Bisceglie A.M., Shiffman M.L., Everson G.T., et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008, 359(23):2429-2441. 10.1056/NEJMoa0707615.
52. Morgan R.L., Baack B., Smith B.D., Yartel A., Pitasi M., Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013, 158(5 Pt 1):329-337. 10.7326/0003-4819-158-5-201303050-00005.
53. De Lope C.R., Tremosini S., Forner A., Reig M., Bruix J. Management of HCC. J Hepatol 2012, 56(suppl 1):S75-S87. 10.1016/S0168-8278(12)60009-9.
54. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362(9399):1907-1917. 10.1016/S0140-6736(03)14964-1.
55. Forner A., Llovet J.M., Bruix J. Hepatocellular carcinoma. Lancet 2012, 379(9822):1245-1255. 10.1016/S0140-6736(11)61347-0.
56. El-Serag H.B. Surveillance for hepatocellular carcinoma: long way to achieve effectiveness. Dig Dis Sci 2012, 57(12):3050-3051. 10.1007/s10620-012-2413-z.
57. Croswell J.M., Ransohoff D.F., Kramer B.S. Principles of cancer screening: lessons from history and study design issues. Semin Oncol 2010, 37(3):202-215. 10.1053/j.seminoncol.2010.05.006.
58. Zhang B.-H., Yang B.-H., Tang Z.-Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004, 130(7):417-422. 10.1007/s00432-004-0552-0.
59. Aghoram R., Cai P., Dickinson J.A. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst Rev 2012, 9:CD002799. 10.1002/14651858.CD002799.pub2.
60. Trevisani F., Cantarini M.C., Labate A.M.M., et al. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol 2004, 99(8):1470-1476. 10.1111/j.1572-0241.2004.30137.x.
61. Yuen M.F., Cheng C.C., Lauder I.J., Lam S.K., Ooi C.G., Lai C.L. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000, 31(2):330-335. 10.1002/hep.510310211.
62. Wong L.L., Limm W.M., Severino R., Wong L.M. Improved survival with screening for hepatocellular carcinoma. Liver Transpl 2000, 6(3):320-325. 10.1053/lv.2000.4875.
63. Sangiovanni A., Del Ninno E., Fasani P., et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004, 126(4):1005-1014.
64. Trevisani F., Santi V., Gramenzi A., et al. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?. Am J Gastroenterol 2007, 102(11):2448-2457. quiz 2458. 10.1111/j.1572-0241.2007.01395.x.
65. Trevisani F., De N.S., Rapaccini G., et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002, 97(3):734-744. 10.1111/j.1572-0241.2002.05557.x.
66. Sarasin F.P., Giostra E., Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996, 101(4):422-434. 10.1016/S0002-9343(96)00197-0.
67. Arguedas M.R., Chen V.K., Eloubeidi M.A., Fallon M.B. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003, 98(3):679-690.
68. Lin O.S., Keeffe E.B., Sanders G.D., Owens D.K. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004, 19(11):1159-1172. 10.1111/j.1365-2036.2004.01963.x.
69. Ruggeri M. Hepatocellular carcinoma: cost-effectiveness of screening. A systematic review. Risk Manag Healthc Policy 2012, 5:49-54. 10.2147/RMHP.S18677.
70. Amarapurkar D., Han K.-H., Chan H.L.-Y., Ueno Y. Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. J Gastroenterol Hepatol 2009, 24(6):955-961. 10.1111/j.1440-1746.2009.05805.x.
71. White D.L., Kanwal F., El-Serag H.B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012, 10(12):1342-1359. e2. 10.1016/j.cgh.2012.10.001.
72. Singal A., Volk M.L., Waljee A., et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009, 30(1):37-47. 10.1111/j.1365-2036.2009.04014.x.
73. Sheu J.C., Sung J.L., Chen D.S., et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985, 89(2):259-266.
74. Trinchet J.-C., Chaffaut C., Bourcier V., et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011, 54(6):1987-1997. 10.1002/hep.24545.
75. Han K.H., Kim do Y., Park J.Y., Ahn S.H., Kim J., Kim S.U., et al. Survival of hepatocellular carcinoma patients may be improved in surveillance interval not more than 6 months compared with more than 6 months: a 15-year prospective study. J Clin Gastroenterol 2013, 47(6):538-544. 10.1097/MCG.0b013e3182755c13.
76. Trevisani F., D'Intino P.E., Morselli-Labate A.M., et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001, 34(4):570-575.
77. Marrero J.A., Feng Z., Wang Y., et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009, 137(1):110-118. 10.1053/j.gastro.2009.04.005.
78. Lok A.S., Sterling R.K., Everhart J.E., et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010, 138(2):493-502. 10.1053/j.gastro.2009.10.031.
79. Di Bisceglie A.M., Sterling R.K., Chung R.T., et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005, 43(3):434-441.
80. Tsukuma H., Hiyama T., Tanaka S., et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993, 328(25):1797-1801. 10.1056/NEJM199306243282501.
81. Zhou X.-D., Tang Z.-Y., Fan J., et al. Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5,829 patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2009, 135(8):1073-1080. 10.1007/s00432-009-0547-y.
82. Paul S.B., Gulati M.S., Sreenivas V., et al. Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein. Oncology 2007, 72(suppl 1):117-123. 10.1159/000111717.
83. Kudo M., Izumi N., Kokudo N., et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011, 29(3):339-364. 10.1159/000327577.
84. Paul S.B., Jaganathan S., Hasan A., et al. Evaluation of hepatocellular carcinoma by contrast enhanced ultrasound: a novel technique. Trop Gastroenterol 2010, 31(3):213-216.
85. Hatanaka K., Kudo M., Minami Y., et al. Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid. Intervirology 2008, 51(suppl 1):61-69. 10.1159/000122600.
86. Colli A., Fraquelli M., Casazza G., et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006, 101(3):513-523. 10.1111/j.1572-0241.2006.00467.x.
87. Forner A., Vilana R., Ayuso C., et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008, 47(1):97-104. 10.1002/hep.21966.
88. Sangiovanni A., Manini M.A., Iavarone M., et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010, 59(5):638-644. 10.1136/gut.2009.187286.
89. Khalili K., Kim T.K., Jang H.-J., et al. Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 2011, 54(4):723-728. 10.1016/j.jhep.2010.07.025.
90. Paul S.B., Gulati M.S. Spectrum of hepatocellular carcinoma on triple phase helical CT: a pictorial essay. Clin Imaging 2002, 26(4):270-279.
91. Karak P.K., Mukhopadhyay S., Berry M. Hepatocellular carcinoma-image morphology in 40 patients. Trop Gastroenterol 1992, 13(1):21-26.
92. Bhargava D.K., Verma K., Dasarathy S. Laparoscopic & histological features of hepatocellular carcinoma. Indian J Med Res 1991, 94:424-425.
93. Lagana S.M., Salomao M., Bao F., Moreira R.K., Lefkowitch J.H., Remotti H.E. Utility of an immunohistochemical panel consisting of Glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma. Appl Immunohistochem Mol Morphol 2013, 21(2):173-179. 10.1097/PAI.0b013e31825d527f.
94. Ahuja A., Gupta N., Kalra N., Srinivasan R., Chawla Y., Rajwanshi A. Role of CD10 immunochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver. Cytopathology 2008, 19(4):229-235. 10.1111/j.1365-2303.2007.00520.x.
95. Swamy M.C., Arathi C., Kodandaswamy C. Value of ultrasonography-guided fine needle aspiration cytology in the investigative sequence of hepatic lesions with an emphasis on hepatocellular carcinoma. J Cytol 2011, 28(4):178-184. 10.4103/0970-9371.86344.
96. Saraswathi A., Malati T. Clinical relevance of alphafetoprotein microheterogeneity in alphafetoprotein-secreting tumors. Cancer Detect Prev 1994, 18(6):447-454.
97. Nayak S.S., Kamath S.S., Kundaje G.N., Aroor A.R. Diagnostic significance of estimation of serum apolipoprotein A along with alpha-fetoprotein in alcoholic cirrhosis and hepatocellular carcinoma patients. Clin Chim Acta 1988, 173(2):157-164.
98. Murugavel K.G., Mathews S., Jayanthi V., et al. Alpha-fetoprotein as a tumor marker in hepatocellular carcinoma: investigations in south Indian subjects with hepatotropic virus and aflatoxin etiologies. Int J Infect Dis 2008, 12(6):e71-76. 10.1016/j.ijid.2008.04.010.
99. Jiang T., Zhu A.X., Sahani D.V. Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. J Hepatol 2013, 58(1):169-177. 10.1016/j.jhep.2012.08.022.
100. Talbot J.-N., Fartoux L., Balogova S., et al. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med 2010, 51(11):1699-1706. 10.2967/jnumed.110.075507.
101. Olthoff K.M., Forner A., Hübscher S., Fung J. What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation?. Liver Transpl 2011, 17(suppl 2):S26-S33. 10.1002/lt.22352.
102. Llovet J.M., Brú C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19(3):329-338. 10.1055/s-2007-1007122.
103. Forner A., Rodríguez-Lopez C., Reig M. Natural history and staging for hepatocellular carcinoma. Clin Liver Dis 2012, 1:183-185.
104. Sarma S., Sharma B., Chawla Y.K., et al. Comparison of 7 staging systems in north Indian cohort of hepatocellular carcinoma. Trop Gastroenterol 2010, 31(4):271-278.
105. Ho C., Chen S., Yeung D.W.C., Cheng T.K.C. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007, 48(6):902-909. 10.2967/jnumed.106.036673.
106. Pal S., Pande G.K. Current status of surgery and transplantation in the management of hepatocellular carcinoma: an overview. J Hepatobiliary Pancreat Surg 2001, 8(4):323-336. 10.1007/s0053410080323.
107. Parikh P., Malhotra H., Jelic S. Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008, 19(suppl 2):ii27-28. 10.1093/annonc/mdn114.
108. Llovet J.M., Fuster J., Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999, 30(6):1434-1440. 10.1002/hep.510300629.
109. Llovet J.M., Schwartz M., Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005, 25(2):181-200. 10.1055/s-2005-871198.
110. Shukla P.J., Barreto S.G. Surgery for malignant liver tumors. J Cancer Res Ther 2009, 5(3):154-160. 10.4103/0973-1482.57119.
111. Marwah S., Khan M.M.R., Chaudhary A., et al. Two hundred and forty-one consecutive liver resections: an experience from India. HPB (Oxford) 2007, 9(1):29-36. 10.1080/13651820600985259.
112. Yao F.Y., Ferrell L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33(6):1394-1403. 10.1053/jhep.2001.24563.
113. Liu F., Wei Y., Wang W., et al. Salvage liver transplantation for recurrent hepatocellular carcinoma within UCSF criteria after liver resection. PLoS ONE 2012, 7(11):e48932. 10.1371/journal.pone.0048932.
114. Abdo A.A., Hassanain M., AlJumah A., et al. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med 2012, 32(2):174-199.
115. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012, 56(4):908-943. 10.1016/j.jhep.2011.12.001.
116. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334(11):693-699. 10.1056/NEJM199603143341104.
117. Jonas S., Bechstein W.O., Steinmüller T., et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001, 33(5):1080-1086. 10.1053/jhep.2001.23561.
118. Befeler A.S., Hayashi P.H., Di Bisceglie A.M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2005, 128(6):1752-1764.
119. Mazzaferro V., Bhoori S., Sposito C., et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011, 17(suppl 2):S44-S57. 10.1002/lt.22365.
120. Chan S.C., Fan S.T., Chok K.S., Cheung T.T., Chan A.C., Fung J.Y., et al. Survival advantage of primary liver transplantation for hepatocellular carcinoma within the up-to-7 criteria with microvascular invasion. Hepatol Int 2012, 6(3):646-656.
121. Landman M.P., Feurer I.D., Pinson C.W., Moore D.E. Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria?. HPB (Oxford) 2011, 13(11):783-791. 10.1111/j.1477-2574.2011.00355.x.
122. Clavien P.-A., Lesurtel M., Bossuyt P.M.M., Gores G.J., Langer B., Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012, 13(1):e11-22. 10.1016/S1470-2045(11)70175-9.
123. Yao F.Y., Xiao L., Bass N.M., Kerlan R., Ascher N.L., Roberts J.P. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007, 7(11):2587-2596. 10.1111/j.1600-6143.2007.01965.x.
124. Volk M.L., Vijan S., Marrero J.A. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 2008, 8(4):839-846. 10.1111/j.1600-6143.2007.02138.x.
125. Llovet J.M., Mas X., Aponte J.J., et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002, 50(1):123-128.
126. Majno P., Giostra E., Mentha G. Management of hepatocellular carcinoma on the waiting list before liver transplantation: time for controlled trials?. Liver Transpl 2007, 13(11 suppl 2):S27-S35. 10.1002/lt.21328.
127. Kaihara S., Kiuchi T., Ueda M., et al. Living-donor liver transplantation for hepatocellular carcinoma. Transplantation 2003, 75(3 suppl l):S37-S40. 10.1097/01.TP.0000047029.02806.16.
128. Todo S., Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004, 240(3):451-459. discussion 459-461.
129. Wakade V.A., Mathur S.K. Donor safety in live-related liver transplantation. Indian J Surg 2012, 74(1):118-126. 10.1007/s12262-011-0385-4.
130. Kakodkar R., Soin A.S. Liver transplantation for HCC: a review. Indian J Surg 2012, 74(1):100-117. 10.1007/s12262-011-0387-2.
131. Yu C.-Y., Ou H.-Y., Huang T.-L., et al. Hepatocellular carcinoma downstaging in liver transplantation. Transplant Proc 2012, 44(2):412-414. 10.1016/j.transproceed.2012.01.043.
132. Lai Q., Avolio A.W., Manzia T.M., et al. Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation. Clin Transplant 2012, 26(2):E125-E131. 10.1111/j.1399-0012.2011.01572.x.
133. Toso C., Asthana S., Bigam D.L., Shapiro A.M.J., Kneteman N.M. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients Database. Hepatology 2009, 49(3):832-838. 10.1002/hep.22693.
134. Hakeem A.R., Young R.S., Marangoni G., Lodge J.P., Prasad K.R. Systematic review: the prognostic role of alpha-fetoprotein following liver transplant for hepatocellular carcinoma. Aliment Pharmacol Ther 2012 Mar 20, 10.1111/j.1365-2036.2012.05060.x.
135. Shrimal A., Prasanth M., Kulkarni A.V. Interventional radiological treatment of hepatocellular carcinoma: an update. Indian J Surg 2012, 74(1):91-99. 10.1007/s12262-011-0377-4.
136. Paul S.B., Gamanagatti S.R., Aneesh M.K., Acharya S.K. Percutaneous ablative therapy for hepatocellular carcinoma. Natl Med J India 2011, 24(6):347-355.
137. Sala M., Llovet J.M., Vilana R., et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004, 40(6):1352-1360. 10.1002/hep.20465.
138. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010, 52(2):762-773. 10.1002/hep.23725.
139. Livraghi T., Bolondi L., Lazzaroni S., et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer 1992, 69(4):925-929.
140. Lencioni R., Bartolozzi C., Caramella D., et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 western patients. Cancer 1995, 76(10):1737-1746.
141. Livraghi T., Giorgio A., Marin G., et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995, 197(1):101-108.
142. Khan K.N., Yatsuhashi H., Yamasaki K., et al. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. J Hepatol 2000, 32(2):269-278.
143. Huo T.I., Huang Y.H., Wu J.C., Lee P.C., Chang F.Y., Lee S.D. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study. Scand J Gastroenterol 2003, 38(7):770-778.
144. Lencioni R., Cioni D., Crocetti L., et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005, 234(3):961-967. 10.1148/radiol.2343040350.
145. Omata M., Tateishi R., Yoshida H., Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004, 127(5 suppl 1):S159-S166.
146. N'Kontchou G., Mahamoudi A., Aout M., et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 western patients with cirrhosis. Hepatology 2009, 50(5):1475-1483. 10.1002/hep.23181.
147. Cho Y.K., Kim J.K., Kim M.Y., Rhim H., Han J.K. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009, 49(2):453-459. 10.1002/hep.22648.
148. Germani G., Pleguezuelo M., Gurusamy K., Meyer T., Isgrò G., Burroughs A.K. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: a meta-analysis. J Hepatol 2010, 52(3):380-388. 10.1016/j.jhep.2009.12.004.
149. Bouza C., López-Cuadrado T., Alcázar R., Saz-Parkinson Z., Amate J.M. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol 2009, 9:31. 10.1186/1471-230X-9-31.
150. Orlando A., Leandro G., Olivo M., Andriulli A., Cottone M. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009, 104(2):514-524. 10.1038/ajg.2008.80.
151. Chhabra D.G., Shah R.C., Parikh V., Jagannath P. Radiofrequency ablation of liver tumors: experience with open and percutaneous approach. Indian J Gastroenterol 2006, 25(2):66-70.
152. Gulati M.S., Batra Y., Paul S.B., Madan K., Ahuja V., Kaul H.K. Radiofrequency ablation: a new therapeutic modality for the management of hepatocellular cancer. Trop Gastroenterol 2002, 23(4):183-185.
153. Tateishi R., Shiina S., Teratani T., et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005, 103(6):1201-1209. 10.1002/cncr.20892.
154. Kapoor A., Kapoor A., Mahajan G. Technical note: radiofrequency ablation of hepatocellular carcinoma with contrast-enhanced ultrasound guidance: first Indian experience. Indian J Radiol Imaging 2011, 21(2):121-123. 10.4103/0971-3026.82296.
155. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 2012, 48(5):599-641. 10.1016/j.ejca.2011.12.021.
156. Chen M.-S., Li J.-Q., Zheng Y., et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006, 243(3):321-328. 10.1097/01.sla.0000201480.65519.b8.
157. Huang J., Yan L., Cheng Z., et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 2010, 252(6):903-912. 10.1097/SLA.0b013e3181efc656.
158. Maini S., Marwaha A. Modeling and simulation of novel antenna for the treatment of hepatocellular carcinoma using finite element method. Electromagn Biol Med 2013 Sep, 32(3):373-381. 10.3109/15368378.2012.721849.
159. Paul S.B., Manjunatha Y.C., Acharya S.K. Palliative treatment in advanced hepatocellular carcinoma: has it made any difference?. Trop Gastroenterol 2009, 30(3):125-134.
160. Srivastava D.N., Thulkar S., Sharma S., et al. Therapeutic radiological interventional procedures in hepatocellular carcinoma. Indian J Gastroenterol 2002, 21(3):96-98.
161. Llovet J.M., Real M.I., Montaña X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359(9319):1734-1739. 10.1016/S0140-6736(02)08649-X.
162. Lo C.-M., Ngan H., Tso W.-K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35(5):1164-1171. 10.1053/jhep.2002.33156.
163. Takayasu K., Arii S., Ikai I., et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006, 131(2):461-469. 10.1053/j.gastro.2006.05.021.
164. Paul S.B., Guglani B., Gulati M.S., Batra Y., Mukhopadhyay S. Transcatheter arterial chemoembolization in hepatocellular carcinoma: technique, effects and present status. Trop Gastroenterol 2003, 24(4):176-184.
165. Rammohan A., Sathyanesan J., Ramaswami S., et al. Embolization of liver tumors: past, present and future. World J Radiol 2012, 4(9):405-412. 10.4329/wjr.v4.i9.405.
166. Lewandowski R.J., Geschwind J.-F., Liapi E., Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology 2011, 259(3):641-657. 10.1148/radiol.11081489.
167. Chung J.W., Park J.H., Han J.K., et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996, 198(1):33-40.
168. Chan A.O., Yuen M.-F., Hui C.-K., Tso W.-K., Lai C.-L. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002, 94(6):1747-1752.
169. Paul S.B., Gamanagatti S.R., Mukund A., Abbas S.Z., Acharya S.K. Transarterial chemoembolization for hepatocellular carcinoma: significance of extrahepatic collateral supply. Indian J Cancer 2011, 48(3):339-344. 10.4103/0019-509X.84941.
170. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. N Engl J Med 1995, 332(19):1256-1261. 10.1056/NEJM199505113321903.
171. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37(2):429-442. 10.1053/jhep.2003.50047.
172. Cammà C., Schepis F., Orlando A., et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002, 224(1):47-54.
173. Paul S.B., Gamanagatti S., Sreenivas V., et al. Trans-arterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma: experience from a tertiary care centre in India. Indian J Radiol Imaging 2011, 21(2):113-120. 10.4103/0971-3026.82294.
174. Oliveri R.S., Wetterslev J., Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011, 3:CD004787. 10.1002/14651858.CD004787.pub2.
175. Varela M., Real M.I., Burrel M., et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007, 46(3):474-481. 10.1016/j.jhep.2006.10.020.
176. Lammer J., Malagari K., Vogl T., et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010, 33(1):41-52. 10.1007/s00270-009-9711-7.
177. Petruzzi N.J., Frangos A.J., Fenkel J.M., et al. Single-center comparison of three chemoembolization regimens for hepatocellular carcinoma. J Vasc Interv Radiol 2013, 24(2):266-273. 10.1016/j.jvir.2012.10.025.
178. Padia S.A., Shivaram G., Bastawrous S., et al. Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles. J Vasc Interv Radiol 2013, 24(3):301-306. 10.1016/j.jvir.2012.11.023.
179. Prajapati H.J., Dhanasekaran R., El-Rayes B.F., et al. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. J Vasc Interv Radiol 2013, 24(3):307-315. 10.1016/j.jvir.2012.11.026.
180. Vadot L., Boulin M., Malbranche C., et al. Result and cost of hepatic chemoembolisation with drug eluting beads in 21 patients. Diagn Interv Imaging 2013, 94(1):53-59. 10.1016/j.diii.2012.05.001.
181. Marelli L., Stigliano R., Triantos C., et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007, 30(1):6-25. 10.1007/s00270-006-0062-3.
182. Morse M.A., Hanks B.A., Suhocki P., et al. Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma. Clin Colorectal Cancer 2012, 11(3):185-190. 10.1016/j.clcc.2011.11.003.
183. Bal C.S., Kumar A. Radionuclide therapy for hepatocellular carcinoma: indication, cost and efficacy. Trop Gastroenterol 2008, 29(2):62-70.
184. Kumar A., Srivastava D.N., Chau T.T.M., et al. Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment-prospective multicenter clinical trial. Radiology 2007, 243(2):509-519. 10.1148/radiol.2432051246.
185. Lewandowski R.J., Kulik L.M., Riaz A., et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009, 9(8):1920-1928. 10.1111/j.1600-6143.2009.02695.x.
186. Salem R., Lewandowski R.J., Mulcahy M.F., et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010, 138(1):52-64. 10.1053/j.gastro.2009.09.006.
187. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(4):378-390. 10.1056/NEJMoa0708857.
188. Cheng A.-L., Kang Y.-K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10(1):25-34. 10.1016/S1470-2045(08)70285-7.
189. Lencioni R., Kudo M., Ye S.-L., et al. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib) non-interventional study. Int J Clin Pract 2012, 66(7):675-683. 10.1111/j.1742-1241.2012.02940.x.
190. Verslype C., Rosmorduc O., Rougier P. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(suppl 7):vii41-48. 10.1093/annonc/mds225.
191. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53(3):1020-1022. 10.1002/hep.24199.
192. Parikh P.M., Fuloria J., Babu G., et al. A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma. Trop Gastroenterol 2005, 26(3):115-118.
193. Pande S.B., Doval D.C., Pavithran K., Sharma J.B., Shirali R., Jena A. Gemcitabine and cisplatin-based combination chemotherapy in advanced hepatocellular carcinoma: an Indian experience. Indian J Med Paediatr Oncol 2012, 33(1):42-47. 10.4103/0971-5851.96968.
194. Sarin S.K., Kumar M., Garg S., Hissar S., Pandey C., Sharma B.C. High dose vitamin K3 infusion in advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2006, 21(9):1478-1482. 10.1111/j.1440-1746.2006.04383.x.
195. Schwarz R.E., Abou-Alfa G.K., Geschwind J.F., Krishnan S., Salem R., Venook A.P. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford) 2010, 12(5):313-320. 10.1111/j.1477-2574.2010.00183.x.
196. Krishnan S., Dawson L.A., Seong J., et al. Radiotherapy for hepatocellular carcinoma: an overview. Ann Surg Oncol 2008, 15(4):1015-1024. 10.1245/s10434-007-9729-5.
197. Hawkins M.A., Dawson L.A. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 2006, 106(8):1653-1663. 10.1002/cncr.21811.
198. Dhir V., Swaroop V.S., Mohandas K.M., et al. Combination chemotherapy and radiation for palliation of hepatocellular carcinoma. Am J Clin Oncol 1992, 15(4):304-307.
199. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
200. Lencioni R., Llovet J.M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010, 30(1):52-60. 10.1055/s-0030-1247132.
201. Zimmerman M.A., Ghobrial R.M., Tong M.J., et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 2008, 143(2):182-188. discussion 188. 10.1001/archsurg.2007.39.
202. Hollebecque A., Decaens T., Boleslawski E., et al. Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantation. Gastroenterol Clin Biol 2009, 33(5):361-369. 10.1016/j.gcb.2009.02.036.
203. Roberts J.P. Tumor surveillance-what can and should be done? Screening for recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2005, 11(suppl 2):S45-S46. 10.1002/lt.20605.
204. Chan S.L., Chan A.T.C., Yeo W. Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both?. Future Oncol 2009, 5(6):889-899. 10.2217/fon.09.64.
205. Bertino G., Neri S., Bruno C.M., et al. Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. Minerva Med 2011, 102(5):363-371.
206. Sturgeon C.M., Duffy M.J., Hofmann B.R., et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010, 56(6):e1-48. 10.1373/clinchem.2009.133124.
207. Induru R.R., Lagman R.L. Managing cancer pain: frequently asked questions. Cleve Clin J Med 2011, 78(7):449-464. 10.3949/ccjm.78a.10054.
208. Koyyalagunta D., Bruera E., Solanki D.R., et al. A systematic review of randomized trials on the effectiveness of opioids for cancer pain. Pain Physician 2012, 15(3 suppl l):ES39-58.
209. Habermehl D., Haase K., Rieken S., Debus J., Combs S.E. Defining the role of palliative radiotherapy in bone metastasis from primary liver cancer: an analysis of survival and treatment efficacy. Tumori 2011, 97(5):609-613. 10.1700/989.10720.
210. Kim J.Y., Kay C.S., Kim Y.S., et al. Helical tomotherapy for simultaneous multitarget radiotherapy for pulmonary metastasis. Int J Radiat Oncol Biol Phys 2009, 75(3):703-710. 10.1016/j.ijrobp.2008.11.065.
211. Kim K., Chie E.K., Kim W., et al. Absence of symptom and intact liver function are positive prognosticators for patients undergoing radiotherapy for lymph node metastasis from hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010, 78(3):729-734. 10.1016/j.ijrobp.2009.08.047.
212. Hsu W.-C., Tsai A.C., Chan S.-C., Wang P.-M., Chung N.-N. Mini-nutritional assessment predicts functional status and quality of life of patients with hepatocellular carcinoma in Taiwan. Nutr Cancer 2012, 64(4):543-549. 10.1080/01635581.2012.675620.
213. Koretz R.L., Avenell A., Lipman T.O. Nutritional support for liver disease. Cochrane Database Syst Rev 2012, 5:CD008344. 10.1002/14651858.CD008344.pub2.
214. Breitbart W., Rosenfeld B., Pessin H., et al. Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA 2000, 284(22):2907-2911.
215. Block S.D., Billings J.A. Patient requests to hasten death. Evaluation and management in terminal care. Arch Intern Med 1994, 154(18):2039-2047.
216. Srivastava D.N., Gandhi D., Julka P.K., Tandon R.K. Gastrointestinal hemorrhage in hepatocellular carcinoma: management with transheptic arterioembolization. Abdom Imaging 2000, 25(4):380-384.
217. Zhu Q., Li J., Yan J.-J., Huang L., Wu M.-C., Yan Y.-Q. Predictors and clinical outcomes for spontaneous rupture of hepatocellular carcinoma. World J Gastroenterol 2012, 18(48):7302-7307. 10.3748/wjg.v18.i48.7302.
218. Lai E.C.H., Lau W.Y. Spontaneous rupture of hepatocellular carcinoma: a systematic review. Arch Surg 2006, 141(2):191-198. 10.1001/archsurg.141.2.191.
219. Gopalakrishnan R., Sundaram J., Sattu K., Pandi A., Thiruvengadam D. Dietary supplementation of silymarin is associated with decreased cell proliferation, increased apoptosis, and activation of detoxification system in hepatocellular carcinoma. Mol Cell Biochem 2013 May, 377(1-2):163-176. 10.1007/s11010-013-1582-1.
220. Thakur S., Singla A., Chawla Y., Rajwanshi A., Kalra N., Arora S.K. Expansion of peripheral and intratumoral regulatory T-cells in hepatocellular carcinoma: a case-control study. Indian J Pathol Microbiol 2011, 54(3):448-453. 10.4103/0377-4929.85073.
221. Amarapurkar A.D., Vibhav, Kim V. Angiogenesis in liver cirrhosis and hepatocellular carcinoma. Indian J Pathol Microbiol 2008, 51(3):323-328.
222. Rasheed Z., Ahmad R., Rasheed N., Ali R. Reactive oxygen species damaged human serum albumin in patients with hepatocellular carcinoma. J Exp Clin Cancer Res 2007, 26(3):395-404.
223. Khan A.A., Jabeen M., Khan A.A., Owais M. Anticancer efficacy of a novel propofol-linoleic acid-loaded escheriosomal formulation against murine hepatocellular carcinoma. Nanomedicine (Lond) 2013 Aug, 8(8):1281-1294. 10.2217/nnm.12.166.